Davita Inc vs Modine Manufacturing Company — how do they compare? Davita Inc trades at $179.25 (market cap $11.29B), while Modine Manufacturing Company trades at $181.56 (market cap $9.66B). The key difference: Davita Inc is the larger of the two by market cap, and Davita Inc is trading nearer its 52-week high, Modine Manufacturing Company nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 114 Days and Modine Manufacturing Company for 33 Days on average.
| DVA | MOD | |
|---|---|---|
Market Cap | $11.29B | $9.66B |
Volume | 582,204 | 1,331,946 |
Sector | Health | Industrials |
52-Week High | $240.96 | $283.95 |
52-Week Low | $103.87 | $110.73 |
Typical Hold Time | 114 Days | 33 Days |
Enterprise Value | $24.01B | $10.09B |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $177.02, up 0.14% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with a P/E of 15 and revenue growth from $13.64B in 2025 to projected $14.0B in 2026. Recent news highlights value-based care expansion with Humana and institutional buying by BlackRock. Technical indicators show resistance at $179 and support at $175, with RSI neutral at 59.72.
DVA presents a mixed outlook: analyst consensus targets $235.67 (33% upside) with 43% buy ratings, but technicals suggest near-term pressure. Key opportunities include consistent EPS beats and partnership growth, while risks involve rising debt-to-asset ratio (65.55% in 2025) and regulatory exposure. Net cash flow turned negative in 2025, requiring monitoring.
Modine Manufacturing (MOD) trades at $181.56, down 4.16% today, amid a bearish technical signal and recent volatility following the completion of its $946 million spin-off of the Performance Technologies unit with Gentherm. Despite the stock's decline, the company has beaten earnings estimates for the last three quarters, with Q3 2026 results pending. Analyst consensus remains strongly bullish with a $331.25 price target, but the technical picture shows resistance near $182 and support at $177.
The outlook for MOD is mixed; strong analyst support and consistent earnings beats contrast with a bearish technical trend and declining net profit margins. Key risks include integration challenges from the spin-off and competitive pressures in thermal management. The stock presents a potential opportunity if upcoming earnings and strategic updates reaffirm growth, but investors should weigh execution risks against the high valuation multiples.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →Modine Manufacturing Company is a global leader in thermal management technology and solutions. The company engineers, manufactures, and markets heat transfer products for a wide range of applications across the automotive, commercial, industrial, and HVAC (heating, ventilation, and air conditioning) markets. Modine's products include engine cooling systems, heat exchangers, and ventilation systems, providing critical thermal solutions for vehicles, data centers, and various equipment worldwide.
Read more on MOD →